ALLIANCE A041702

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Leukemia

Status:

Closed

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

NCT#03737981

Eligible for screening study DCP 001

 A041702 is closed to accrual, effective July 15, 2022

 A041702, Step 1 registration, is closed to accrual, effective November 1, 2022